BACKGROUND: Multimodality therapy may prolong survival among resectable malignant pleural mesothelioma (MPM). However, the role of adjuvant radiation remains controversial. We explored a large nationwide database to determine whether adjuvant radiation is associated with improved survival. METHODS: The National Cancer Database (NCDB) was queried to identify patients with MPM who received cancer-directed surgery between 2004-2013. Adjuvant radiation included intensity modulated radiation therapy or conformal 3D radiation. Propensity matching was performed with a 150-day landmark to address survivorship bias. Cox regression was used with an interaction term between pathologic stage and radiation. RESULTS: A total of 2,846 patients were identified as having undergone cancer-directed surgery for MPM; among whom 213 (7%) received adjuvant radiation. Adjuvant radiation was associated with improved survival among those who were stage I-II (P=0.024), but not stage III or IV (P=0.890 and P=0.183, respectively). After propensity matching, adjuvant radiation was associated with improved survival for those who were stage I-II [hazard ratio (HR) 0.52, P=0.035], whereas no similar effect was observed for those who were stage III or IV (P=0.190 and P=0.562, respectively). Multivariable regression revealed that sarcomatoid histology (HR 1.80, P=0.018) and stage IV disease (HR 1.65, P=0.033) were also associated with worse survival. CONCLUSIONS: Adjuvant radiation was associated with improved survival among those with pathologic stage I-II MPM. No survival advantage was observed for those with pathologic stage III or stage IV MPM, however. Our results justify the need for further prospective trials to investigate the utility of adjuvant radiotherapy among those with MPM.
BACKGROUND: Multimodality therapy may prolong survival among resectable malignant pleural mesothelioma (MPM). However, the role of adjuvant radiation remains controversial. We explored a large nationwide database to determine whether adjuvant radiation is associated with improved survival. METHODS: The National Cancer Database (NCDB) was queried to identify patients with MPM who received cancer-directed surgery between 2004-2013. Adjuvant radiation included intensity modulated radiation therapy or conformal 3D radiation. Propensity matching was performed with a 150-day landmark to address survivorship bias. Cox regression was used with an interaction term between pathologic stage and radiation. RESULTS: A total of 2,846 patients were identified as having undergone cancer-directed surgery for MPM; among whom 213 (7%) received adjuvant radiation. Adjuvant radiation was associated with improved survival among those who were stage I-II (P=0.024), but not stage III or IV (P=0.890 and P=0.183, respectively). After propensity matching, adjuvant radiation was associated with improved survival for those who were stage I-II [hazard ratio (HR) 0.52, P=0.035], whereas no similar effect was observed for those who were stage III or IV (P=0.190 and P=0.562, respectively). Multivariable regression revealed that sarcomatoid histology (HR 1.80, P=0.018) and stage IV disease (HR 1.65, P=0.033) were also associated with worse survival. CONCLUSIONS: Adjuvant radiation was associated with improved survival among those with pathologic stage I-II MPM. No survival advantage was observed for those with pathologic stage III or stage IV MPM, however. Our results justify the need for further prospective trials to investigate the utility of adjuvant radiotherapy among those with MPM.
Authors: P E Van Schil; P Baas; R Gaafar; A P Maat; M Van de Pol; B Hasan; H M Klomp; A M Abdelrahman; J Welch; J P van Meerbeeck Journal: Eur Respir J Date: 2010-06-04 Impact factor: 16.671
Authors: B C John Cho; Ron Feld; Natasha Leighl; Isabelle Opitz; Masaki Anraku; Ming-Sound Tsao; David M Hwang; Andrew Hope; Marc de Perrot Journal: J Thorac Oncol Date: 2014-03 Impact factor: 15.609
Authors: Federico Rea; Giuseppe Marulli; Luigi Bortolotti; Cristiano Breda; Adolfo Gino Favaretto; Lucio Loreggian; Francesco Sartori Journal: Lung Cancer Date: 2007-04-02 Impact factor: 5.705
Authors: William W Chance; David C Rice; Pamela K Allen; Anne S Tsao; Hiral P Fontanilla; Zhongxing Liao; Joe Y Chang; Chad Tang; Hubert Y Pan; James W Welsh; Reza J Mehran; Daniel R Gomez Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-25 Impact factor: 7.038
Authors: V W Rusch; K Rosenzweig; E Venkatraman; L Leon; A Raben; L Harrison; M S Bains; R J Downey; R J Ginsberg Journal: J Thorac Cardiovasc Surg Date: 2001-10 Impact factor: 5.209
Authors: David C Rice; Craig W Stevens; Arlene M Correa; Ara A Vaporciyan; Anne Tsao; Kenneth M Forster; Garrett L Walsh; Stephen G Swisher; Wayne L Hofstetter; Reza J Mehran; Jack A Roth; Zhongxing Liao; W Roy Smythe Journal: Ann Thorac Surg Date: 2007-11 Impact factor: 4.330
Authors: Valerie W Rusch; Dorothy Giroux; Catherine Kennedy; Enrico Ruffini; Ayten K Cangir; David Rice; Harvey Pass; Hisao Asamura; David Waller; John Edwards; Walter Weder; Hans Hoffmann; Jan P van Meerbeeck Journal: J Thorac Oncol Date: 2012-11 Impact factor: 15.609
Authors: Marc de Perrot; Ronald Feld; B C John Cho; Andrea Bezjak; Masaki Anraku; Ronald Burkes; Heidi Roberts; Ming S Tsao; Natasha Leighl; Shaf Keshavjee; Michael R Johnston Journal: J Clin Oncol Date: 2009-02-17 Impact factor: 44.544
Authors: Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544